Positron Corporation (POSC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Positron Corporation (POSC) trades at $1.82 with AI Score 45/100 (Grade C). Positron Corporation specializes in cardiac positron emission tomography (PET) imaging, offering scanners, services, and financing solutions. Market cap: $59.8M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for POSC: POSC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates POSC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
POSC: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Positron Corporation (POSC) Healthcare & Pipeline Overview
Positron Corporation focuses on cardiac PET imaging, providing attrius PET scanners, clinical services, and financing in the U.S. market. With a negative profit margin and trading on the OTC market, the company aims to improve cardiac disease diagnosis through cost-effective solutions, facing competition from established medical device companies.
What Is the Investment Thesis for POSC?
Positron Corporation's investment thesis hinges on the increasing demand for accurate and cost-effective cardiac diagnostic tools. The company's attrius PET scanner and related services target a critical need in the healthcare sector. However, with a negative profit margin of -766.1% and gross margin of -136.0%, the company faces significant financial challenges. The company's future relies on its ability to improve profitability and expand its market presence. Key catalysts include potential partnerships with larger healthcare providers and successful commercialization of its technology. The negative beta of -0.08 suggests a potential buffer against market volatility, but the OTC market listing introduces liquidity and regulatory risks.
Based on FMP financials and quantitative analysis
POSC Key Highlights
Market capitalization of $59.8M indicates a micro-cap company with high growth potential but also higher risk.
- P/E ratio of -15.37 reflects the company's current lack of profitability.
- Negative profit margin of -766.1% highlights significant challenges in achieving profitability.
- Gross margin of -136.0% indicates that the company's cost of goods sold exceeds its revenue.
- Beta of -0.08 suggests that the stock is less volatile than the market, but this may also reflect limited trading activity.
Who Are POSC's Competitors?
POSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASAPF Aurora Spine Corporation | $0.17 | -2.73% | $13.0M | 48 |
| EMITF Elbit Imaging Ltd. | $1.60 | +0.00% | $21.3M | 42 |
| FNCH Finch Therapeutics Group, Inc. | $10.20 | +0.99% | $16.4M | — |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| CKMTF Carmat S.A. | $12.75 | -50.96% | $85.2M | 61 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.5M | 68 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are POSC's Key Strengths?
Specialized focus on cardiac PET imaging.
- Proprietary attrius PET scanner technology.
- Integrated clinical and technical service offerings.
- Financing solutions to facilitate adoption.
What Are POSC's Weaknesses?
Negative profit margin and gross margin.
- Limited market capitalization.
- Dependence on a single product (attrius PET scanner).
- OTC market listing introduces liquidity and regulatory risks.
What Could Drive POSC Stock Higher?
Potential partnerships with larger healthcare providers to expand market reach.
- Continued commercialization of the attrius PET scanner and related services.
- Development of new applications for the attrius PET scanner in other areas of nuclear medicine.
- Expansion into new geographic markets with growing healthcare infrastructure.
- Integration of telemedicine capabilities for remote diagnostics and consultations.
What Are the Key Risks for POSC?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies with greater resources.
- Technological advancements that could render the attrius PET scanner obsolete.
- Changes in healthcare regulations and reimbursement policies that could impact profitability.
- Negative profit margin and gross margin pose a significant financial challenge.
- OTC market listing introduces liquidity and regulatory risks.
What Are the Growth Opportunities for POSC?
- Expansion into new geographic markets: Positron Corporation can explore opportunities to expand its operations beyond the United States. International markets, particularly in regions with growing healthcare infrastructure and increasing prevalence of cardiac diseases, could present significant growth potential. This expansion would require navigating regulatory hurdles and establishing distribution networks, but could significantly increase revenue streams. The global medical devices market is projected to reach $600 billion by 2028, providing a substantial addressable market.
- Development of new applications for the attrius PET scanner: Positron Corporation can invest in research and development to explore new applications for its attrius PET scanner beyond cardiac imaging. This could include applications in other areas of nuclear medicine, such as oncology or neurology. Expanding the scanner's capabilities would broaden its market appeal and create new revenue opportunities. The nuclear medicine market is expected to grow at a CAGR of 6% over the next five years.
- Strategic partnerships with healthcare providers: Positron Corporation can form strategic partnerships with hospitals, clinics, and other healthcare providers to promote the adoption of its attrius PET scanner. These partnerships could involve joint marketing efforts, training programs, and collaborative research projects. By working closely with healthcare providers, Positron can increase its market visibility and build a strong customer base. The timeline for establishing these partnerships is ongoing.
- Offering comprehensive service and maintenance packages: Positron Corporation can enhance its revenue streams by offering comprehensive service and maintenance packages for its attrius PET scanner. These packages could include regular maintenance checks, software updates, and technical support. By providing ongoing support to its customers, Positron can ensure the optimal performance of its scanners and build long-term relationships. This recurring revenue model can stabilize the company's financial performance.
- Leveraging telemedicine for remote diagnostics: Positron Corporation can integrate telemedicine capabilities into its service offerings, allowing for remote diagnostics and consultations. This would enable healthcare providers in remote or underserved areas to access specialized expertise in cardiac PET imaging. Telemedicine is a rapidly growing field, and its integration with Positron's technology could significantly expand its market reach. The global telemedicine market is projected to reach $400 billion by 2027.
What Are POSC's Competitive Advantages?
- Specialized focus on cardiac PET imaging.
- Proprietary attrius PET scanner technology.
- Integrated clinical and technical service offerings.
- Financing solutions to facilitate adoption.
What Does POSC Do?
Positron Corporation, established in 1983 and based in Niagara Falls, New York, operates as a nuclear medicine healthcare company specializing in cardiac positron emission tomography (PET) imaging. The company's core business revolves around providing solutions for the diagnosis of cardiac disease, with the goal of improving patient outcomes and enabling cost-effective medical practices. Positron's primary offering is the attrius PET scanner, which allows healthcare providers to perform cardiac imaging. In addition to the scanner, Positron provides a range of clinical and technical services to support the use of its technology. These services include training, maintenance, and support to ensure that healthcare providers can effectively utilize the attrius PET scanner. Furthermore, Positron Corporation offers financing solutions to assist healthcare providers in acquiring the attrius PET scanner. This includes leasing options and other financial arrangements designed to make the technology accessible to a wider range of medical facilities. The company operates exclusively in the United States.
What Products and Services Does POSC Offer?
- Specializes in cardiac positron emission tomography (PET) imaging.
- Offers the attrius PET scanner for cardiac disease diagnosis.
- Provides clinical and technical services to support the use of its technology.
- Offers financing solutions to assist healthcare providers in acquiring the attrius PET scanner.
- Aims to improve patient outcomes through accurate cardiac disease diagnosis.
- Enables healthcare providers to practice cost-effective medicine.
How Does POSC Make Money?
- Sells attrius PET scanners to healthcare providers.
- Generates revenue from clinical and technical services related to the scanner.
- Provides financing solutions, potentially earning interest or fees.
- Focuses on the U.S. market for cardiac PET imaging.
What Industry Does POSC Operate In?
Positron Corporation operates within the medical devices industry, specifically focusing on cardiac imaging. The market for cardiac diagnostic tools is driven by the increasing prevalence of heart disease and the need for early and accurate diagnosis. The industry is competitive, with established players like FNCH and GBLP offering a range of imaging solutions. Positron's success depends on its ability to differentiate its technology and capture market share in a landscape characterized by technological advancements and evolving healthcare regulations.
Who Are POSC's Key Customers?
- Hospitals and medical centers.
- Cardiology clinics.
- Healthcare providers specializing in cardiac diagnostics.
How Positron Corporation Is Valued
Positron Corporation carries a market capitalization of $59.8M, placing it in the micro-cap category. Relative to its peer group, POSC's quantitative score of 45/100 is roughly in line with the peer average of 53/100.
Company Profile
Positron Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in North Tonawanda, US. The company is led by CEO Adel Abdullah. POSC has traded publicly since 1999.
Key Financial Metrics
Its free cash flow yield is -19.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -18.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Positron Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
POSC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on cardiac PET imaging.
- Proprietary attrius PET scanner technology.
- Integrated clinical and technical service offerings.
- Financing solutions to facilitate adoption.
Bear Case
- Negative profit margin and gross margin.
- Limited market capitalization.
- Dependence on a single product (attrius PET scanner).
- OTC market listing introduces liquidity and regulatory risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
POSC Latest News
No recent news available for POSC.
POSC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for POSC.
Price Targets
Wall Street price target analysis for POSC.
POSC MoonshotScore
What does this score mean?
The MoonshotScore rates POSC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Adel Abdullah
CEO
Adel Abdullah serves as the CEO of Positron Corporation, leading a team of 19 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background profile cannot be constructed at this time. Further research would be required to ascertain his qualifications and experience prior to joining Positron Corporation.
Track Record: Due to the limited information available, it is not possible to assess Adel Abdullah's track record at Positron Corporation. Key achievements, strategic decisions, and company milestones under his leadership cannot be determined based on the provided data. Further information would be needed to evaluate his performance and contributions to the company's progress.
POSC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Positron Corporation may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, or are undergoing financial distress. Unlike NYSE or NASDAQ listings, OTC Other stocks face fewer regulatory requirements, resulting in increased risks for investors due to potential lack of transparency and information.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- OTC Other tier status indicates a higher risk of financial distress or operational challenges.
- Potential for delisting or suspension from the OTC market due to non-compliance with regulations.
- Limited analyst coverage and institutional interest can result in less informed market valuations.
- Verify the company's financial statements and disclosures, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Review any legal or regulatory filings related to the company.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any news or press releases that may impact the company's stock price.
- The company has been in operation since 1983.
- Positron Corporation focuses on cardiac PET imaging.
- Offers attrius PET scanner, clinical and technical services, and financing solutions.
Positron Corporation Healthcare Stock: Key Questions Answered
What does the AI Score mean for POSC?
POSC holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Positron Corporation specializes in cardiac positron emission tomography (PET) imaging, offering scanners, services, and financing solutions. The company operates in the United States, focusing …
What does Positron Corporation do?
Positron Corporation specializes in cardiac positron emission tomography (PET) imaging. The company offers the attrius PET scanner, clinical and technical services, and financing solutions to healthcare providers. Its focus is on enabling accurate diagnosis of cardiac disease, improving patient outcomes, and promoting cost-effective medical practices within the U.S. healthcare market. The company aims to provide comprehensive solutions for cardiac imaging needs.
What do analysts say about POSC stock?
Currently, there is no available analyst coverage for Positron Corporation (POSC) due to its OTC listing and small market capitalization. Key valuation metrics such as revenue projections and earnings estimates are not readily available. Investors should conduct their own thorough research and consider the risks associated with investing in micro-cap OTC stocks before making any investment decisions. The company's growth potential is uncertain given its current financial challenges.
What are the main risks for POSC?
The main risks for Positron Corporation include its negative profit and gross margins, indicating financial instability. Competition from larger, more established medical device companies poses a threat. Technological advancements could render their current technology obsolete. Being listed on the OTC market introduces liquidity risks and regulatory uncertainties. Changes in healthcare regulations and reimbursement policies could also negatively impact the company's profitability.
What are the key factors to evaluate for POSC?
Positron Corporation (POSC) holds an AI score of 45/100 (low). Positron Corporation's investment thesis hinges on the increasing demand for accurate and cost-effective cardiac diagnostic tools. Not financial advice.
How frequently does POSC data refresh on this page?
POSC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven POSC's recent stock price performance?
Positron Corporation (POSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on cardiac PET imaging. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider POSC overvalued or undervalued right now?
Positron Corporation (POSC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research POSC before investing?
Before investing in Positron Corporation (POSC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market listing introduces higher risks compared to major exchanges.
- AI analysis pending for POSC.